vesnarinone
Small moleculeexperimental
Vesnarinone (INN) is a cardiotonic agent. A mixed phosphodiesterase 3 inhibitor and ion-channel modifier that has modest, dose-dependent, positive inotropic activity, but minimal negative chronotropic activity. Vesnarinone improves ventricular performance most in patients with the worst degree of heart failure. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002130)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C(=O)N2CCN(c3ccc4c(c3)CCC(=O)N4)CC2)cc1OC- Mol. weight
- 395.46 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaVesnarinone ↗
- ChEMBLCHEMBL17423 ↗
Also known as
- 3,4-dihydro-6-(4-(3,4-dimethoxybenzoyl)-1-piperazinyl)-2-1h-quinolinone
- arkin
- arkin
- opc 8212
- opc-8212
- opc-8212
- opc-8212
- opc-8212
- pieranometazine
- vesnarinone
- vesnarinone
- vesnarinone
- vesnarinone
- vesnarinone
- vesnarinone
- vesnarinone
- vesnarinone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002129 | Phase 1 | Nov 2, 1999 | Otsuka |
| NCT00002130 | N/A | Nov 2, 1999 | Otsuka |
| NCT00002131 | Phase 2 | Nov 2, 1999 | Otsuka |
| NCT00002337 | Phase 1 | Nov 2, 1999 | Otsuka |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 4 | 4 | 3 | 1999 |
1 organizations
Page 1 / 1